I found this article on the NASDAQ GlobeNewswire regarding how CBD can help children battle cancer.
PharmaCyte Biotech, Inc is a clinical-stage biotechnology company focused on finding targeted solutions to cancer and diabetes. Their signature technology utilizes live-cell encapsulation which they call “Cell-in-a-Box”. PharmaCyte is focused on finding a cannabinoid-based targeted therapy for brain cancer. Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine published an article supporting PharmaCyte’s efforts. This article can be found on PubMed and the article was originally published in Children’s Nervous System.
“Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system” provides evidence supporting the role of the endocannabinoid system in body homeostasis and therefore tumor control. Pediatric low-grade gliomas are a group of tumors that make up a majority of juvenile CNS tumors.
It was seen after partial surgical removal, a tumor that remained stable or exhibited spontaneous involution expressed cnr1 at a much higher rate at the time of diagnosis. High expression of cnr1 in the tumors that remained stable or died suggests they are more susceptible to our circulating endocannabinoid molecules – most notably the primary CNR1 agonist Anandamide. It is important to note, the use of cannabinoids derived from Cannabis sativa L. may provide a stronger reaction for a few reasons…
- Cannabis-derived cannabinoids aid in the inhibition Fatty Acid Amide Hydrolase – the enzyme that acts to quickly degrade endocannabinoids
- a wide range of cannabinoids and terpenes can be extracted from the plant leading to an “Entourage Effect” – enhancing endocannabinoid action
- works directly alongside endocannabinoids in binding to endocannabinoid receptors
The study was done via an integrated molecular analysis…
- high throughput gene expression
- microRNA data expression of primary, untreated tumors from patients with the Pediatric low-grade gliomas (must have undergone a surgery at the hospital and had at least a 10-year follow-up)
As always, new scientific studies prove the effectiveness of Cannabinoid therapy. One can only wonder when the first approved application will be released. It’s for the people!